Long-Term Maintenance Therapy: Sustaining Remission with Ketamine

The initial response to ketamine is often dramatic, with patients experiencing rapid relief from depression that may have plagued them for years. However, the transient nature of ketamine's effects presents a significant clinical challenge. Without ongoing treatment, most patients relapse within 2-4 weeks of their last infusion. This reality has led to the development of maintenance strategies designed to sustain the gains achieved during acute treatment. This article examines the evidence for maintenance ketamine therapy, practical protocols for frequency optimization, strategies for preventing tolerance, and guidance on transitioning patients to alternative long-term treatments.

The Rationale for Maintenance Therapy

The Natural History of Ketamine Response

Understanding the typical trajectory of ketamine response informs maintenance strategies:

Acute Response Phase (Days 1-7):

• Peak antidepressant effect typically 24-72 hours post-infusion
• Approximately 50-70% of patients achieve response after a single infusion
• Effects begin to wane by day 5-7

Relapse Trajectory (Weeks 2-4):

• Without additional treatment, median time to relapse is 18-19 days
• By week 4, approximately 70-80% of responders have relapsed
• Relapse patterns vary considerably between individuals

Implications: The biological effects of ketamine, particularly enhanced synaptic plasticity, appear time-limited. Maintenance treatment may be necessary to sustain structural and functional changes in neural circuits.

Goals of Maintenance Therapy

Effective maintenance therapy aims to:

1. Sustain Remission: Prevent return of depressive symptoms
2. Optimize Function: Allow patients to engage fully in work, relationships, and life
3. Enable Other Treatments: Create a window for psychotherapy and medication optimization
4. Minimize Treatment Burden: Find the lowest effective frequency
5. Ensure Safety: Monitor for long-term adverse effects
6. Plan for Transition: Work toward treatments with longer durability

Evidence for Maintenance Ketamine

Clinical Trial Evidence

Several studies support the efficacy of maintenance ketamine:

Murrough et al. (2013): In an extension study, patients who responded to acute ketamine treatment were offered weekly maintenance infusions. Those continuing treatment maintained response significantly longer than historical controls.

Phillips et al. (2019): A randomized discontinuation trial showed that patients receiving maintenance ketamine (weekly) had significantly lower relapse rates than those switched to placebo after acute response.

SUSTAIN-1 and SUSTAIN-2 Trials (Esketamine): These pivotal trials demonstrated that continued esketamine treatment (weekly or every 2 weeks) significantly delayed relapse compared to placebo discontinuation.

Real-World Evidence: Multiple case series and clinic audits report that patients maintained on ketamine at individualized intervals can sustain response for months to years.

Meta-Analytic Findings

A 2024 meta-analysis of maintenance ketamine studies (n=412 patients across 8 studies) found:

• 65% of acute responders maintained response at 3 months with ongoing treatment
• 52% maintained response at 6 months
• Optimal maintenance frequency ranged from weekly to monthly, depending on individual factors

Maintenance Protocols

Protocol Development Approach

Effective maintenance requires individualized protocols based on:

1. Response Durability: How quickly symptoms return after treatment
2. Symptom Trajectory: Pattern of relapse (gradual vs. sudden)
3. Treatment Tolerability: Side effect profile at various frequencies
4. Practical Factors: Cost, access, and lifestyle considerations
5. Concurrent Treatments: Medications and therapy engagement

Standard Maintenance Protocol

Phase 1: Response Stabilization (Weeks 1-4)

• Complete acute series (6 infusions over 2-3 weeks)
• Confirm response (≥50% reduction in MADRS)
• Assess response durability pattern

Phase 2: Frequency Finding (Weeks 5-12)

• Begin with weekly infusions
• Assess symptoms before each treatment
• If stable for 4 weeks, extend to every 10 days

Phase 3: Optimization (Weeks 13-24)

• Continue extending interval if symptoms stable
• Target: Every 2 weeks or longer
• Establish individual optimal frequency

Phase 4: Long-Term Maintenance (Month 6+)

• Maintain at optimal frequency
• Regular reassessment (quarterly)
• Consider transition options

Interval Extension Protocol

Acute Response Achieved (Week 3)
    ↓
Weekly Infusions × 4 weeks
    ↓ (If stable)
Every 10 days × 3 treatments
    ↓ (If stable)
Every 2 weeks × 4 treatments
    ↓ (If stable)
Every 3 weeks × 3 treatments
    ↓ (If stable)
Monthly maintenance (or continue extending)

Extension Rules:

• Extend interval only if MADRS remains ≤10 or at least 50% below acute baseline
• If symptoms increase >25% from maintenance nadir, return to previous interval
• Allow 2-3 treatments at each interval before extending

Symptom-Triggered Protocol

An alternative approach uses symptom monitoring to guide treatment timing:

Daily Monitoring:

• Patient completes daily PHQ-2 or similar brief measure
• Establishes personal symptom threshold

Treatment Triggers:

• Sustained increase >25% above maintenance baseline for 3+ days
• Return of specific sentinel symptoms (identified individually)
• Functional impairment noticed by patient or family

Advantages:

• Maximally individualized
• May reduce treatment frequency
• Empowers patient self-monitoring

Disadvantages:

• Requires engaged, insightful patient
• May result in delayed treatment during relapse
• More variable scheduling

Hybrid Protocol

Combines scheduled maintenance with PRN flexibility:

Base Frequency: Monthly infusions as standard PRN Boosters: Additional infusions available if symptoms breakthrough Monitoring: Weekly symptom tracking Review: Monthly assessment of frequency adequacy

Preventing Tolerance

Understanding Tolerance Mechanisms

Tolerance to ketamine can develop through multiple mechanisms:

Pharmacodynamic Tolerance:

• NMDA receptor upregulation
• Compensatory glutamatergic changes
• Downstream signaling adaptations

Pharmacokinetic Tolerance:

• Enzyme induction increasing metabolism
• Less common with intermittent dosing

Pseudotolerance:

• Progression of underlying disease
• Development of comorbidities
• Psychosocial factors

Clinical Evidence on Tolerance

The evidence on ketamine tolerance in depression treatment is reassuring but nuanced:

Long-Term Studies: Multiple studies following patients for 1-2+ years have not demonstrated consistent tolerance development when using intermittent maintenance dosing.

Dose Escalation Data: Most patients do not require dose increases over time when treatment intervals are appropriately spaced.

Individual Variation: A minority of patients (estimated 10-20%) may experience some tolerance, requiring dose adjustment or interval modification.

Tolerance Prevention Strategies

1. Optimize Treatment Intervals

The most effective tolerance prevention strategy is appropriate spacing of treatments:

• Avoid more frequent than weekly dosing long-term
• Target the longest effective interval
• Use symptom monitoring to guide timing

2. Drug Holidays

For patients showing early tolerance signs:

• Consider 4-6 week treatment pause
• Reinitiate at previous effective dose
• May "reset" receptor sensitivity

3. Route Rotation

Theoretical benefit from alternating administration routes:

• Different pharmacokinetic profiles may reduce adaptation
• IV → Intranasal → Sublingual rotation
• Limited evidence but clinical rationale exists

4. Dose Optimization

Rather than escalating doses:

• First, shorten interval
• Consider divided dosing (lower dose, more frequent)
• Avoid doses >0.5 mg/kg unless clearly indicated

5. Concurrent Treatment Optimization

Maximize non-ketamine treatments to reduce ketamine burden:

• Optimize antidepressants
• Intensify psychotherapy during ketamine response
• Address modifiable factors (sleep, exercise, stress)

Managing Suspected Tolerance

Assessment:

1. Verify true tolerance vs. disease progression
2. Review treatment adherence and concurrent medications
3. Assess for new stressors or comorbidities
4. Consider plasma ketamine levels if available

Management Options:

| Presentation | Strategy | |-------------|----------| | Gradual response diminution | Shorten interval before increasing dose | | Maintained peak effect, shorter duration | Increase frequency | | Reduced peak effect | Consider dose increase or drug holiday | | Complete loss of response | Drug holiday, then reassess |

Long-Term Monitoring

Safety Monitoring Protocol

Chronic ketamine use requires systematic monitoring:

Cognitive Assessment:

• Baseline MOCA or similar screening
• Repeat every 6 months
• Detailed neuropsychological testing if concerns arise

Urological Monitoring:

• Baseline urinalysis
• Symptom inquiry at each visit (frequency, urgency, pain)
• Urinalysis every 3-6 months
• Urology referral if symptoms develop

Hepatic Monitoring:

• Baseline LFTs
• Repeat every 3-6 months
• If elevated, consider frequency reduction or cessation

Cardiovascular Monitoring:

• Blood pressure at each visit
• ECG annually or if symptoms
• Assess for development of hypertension

Psychiatric Monitoring:

• Ongoing mood assessment
• Monitor for dissociative symptoms between treatments
• Screen for substance use
• Assess for emerging psychotic symptoms

Long-Term Safety Data

Current evidence on long-term ketamine safety in depression treatment:

Cognitive Effects: Studies of patients receiving maintenance ketamine for 1-2 years have not demonstrated cognitive decline. This differs from chronic recreational use, likely due to lower doses and frequencies.

Urological Effects: Cystitis and bladder dysfunction, common in recreational users, are rare in therapeutic use. The much lower cumulative exposure appears to be protective.

Hepatic Effects: Occasional LFT elevations reported; typically resolve with frequency reduction. Severe hepatotoxicity not reported in therapeutic use.

Abuse Potential: In structured medical settings, abuse and diversion rates are very low. Patients with substance use history require additional monitoring.

Documentation for Long-Term Treatment

Comprehensive documentation supports quality care and risk management:

Every Visit:

• Symptom assessment (standardized scale)
• Side effects review
• Vital signs
• Substance use screening
• Treatment response assessment

Quarterly:

• Comprehensive psychiatric assessment
• Treatment plan review
• Laboratory monitoring as indicated
• Goal setting for next quarter

Annually:

• Full safety assessment
• Cognitive screening
• Discussion of treatment continuation vs. transition
• Consent re-affirmation

Transitioning to Other Treatments

When to Consider Transition

Not all patients will require indefinite ketamine maintenance. Consider transition when:

Stable Remission Achieved:

• Sustained remission for 6+ months
• Other treatments optimized
• Strong psychotherapy engagement
• Functional recovery achieved

Tolerance Developing:

• Escalating dose requirements
• Diminishing response duration
• Approaching safety thresholds

Patient Preference:

• Desire to reduce treatment burden
• Access or cost concerns
• Planning for pregnancy

Safety Concerns:

• Urological symptoms
• Hepatic abnormalities
• Cognitive complaints
• Substance use concerns

Transition Strategies

Gradual Taper:

Current Frequency: Every 2 weeks
    ↓
Every 3 weeks × 3 months
    ↓
Monthly × 3 months
    ↓
Every 6 weeks × 3 months
    ↓
Discontinue with PRN availability

Bridge to Other Treatments:

• Maximize antidepressant therapy during ketamine response
• Intensify psychotherapy
• Consider TMS as transitional treatment
• Establish relapse prevention plan

Abrupt Discontinuation:

• Generally safe from physiological standpoint
• Risk of rapid relapse
• Reserved for safety concerns requiring immediate cessation

Relapse Prevention Planning

Before discontinuing maintenance:

1. Optimize Other Treatments

   • Antidepressant at therapeutic dose
   • Active psychotherapy engagement
   • Lifestyle factors addressed

2. Establish Early Warning Signs

   • Individual relapse signatures
   • Sleep changes
   • Anhedonia return
   • Cognitive symptoms

3. Create Action Plan

   • What to do if symptoms emerge
   • How to access booster treatment
   • Support system activation

4. Schedule Follow-Up

   • Monthly initially after discontinuation
   • Then quarterly for 1 year
   • PRN availability emphasized

Managing Relapse After Discontinuation

If relapse occurs after maintenance discontinuation:

Early Relapse (< 1 month):

• Consider inadequate stabilization
• Reinitiate maintenance at previous frequency
• Extend stabilization period before next taper attempt

Intermediate Relapse (1-3 months):

• Single infusion or short series may restore response
• Reassess optimal maintenance strategy
• Consider adjunctive treatments

Late Relapse (> 3 months):

• May respond to standard acute series
• Evaluate for new factors contributing to relapse
• Develop revised maintenance plan

Special Considerations

Pregnancy Planning

For patients considering pregnancy:

• Discuss ketamine discontinuation well before conception
• Transition to pregnancy-compatible treatments
• Ketamine should be avoided during pregnancy
• Plan for postpartum relapse risk

Surgical Procedures

For patients requiring surgery:

• Inform anesthesiologist of ketamine treatment
• Continue maintenance through minor procedures
• May need to adjust around major surgeries
• Monitor for altered anesthetic requirements

Travel and Access

For patients who travel frequently:

• Establish relationships with providers in other locations
• Consider portable routes (intranasal, sublingual)
• Plan treatment timing around travel
• Document treatment for other providers

Cost and Insurance

Long-term financial sustainability:

• Insurance coverage varies significantly
• Document medical necessity thoroughly
• Consider cash-pay options and sliding scale
• Intranasal esketamine may have different coverage
• Explore patient assistance programs

Case Examples

Case 1: Successful Long-Term Maintenance

Patient: 45-year-old woman with treatment-resistant depression since age 30. Failed 8 antidepressant trials and 2 TMS courses.

Acute Response: Achieved remission (MADRS 4) after 6 IV ketamine infusions.

Maintenance Course:

• Weeks 4-8: Weekly infusions, maintained remission
• Weeks 9-16: Extended to every 10 days, stable
• Weeks 17-32: Every 2 weeks, stable
• Month 8+: Monthly infusions

2-Year Outcome: Maintained on monthly ketamine infusions. MADRS consistently <8. Returned to full-time work. No tolerance development. Annual monitoring normal.

Case 2: Successful Transition

Patient: 38-year-old man with MDD and anxiety, responded well to acute ketamine.

Maintenance: Every 2-week infusions for 8 months, stable remission.

Transition:

• During ketamine response, optimized to duloxetine 120mg
• Engaged in weekly CBT for 6 months
• Gradual taper: every 3 weeks × 3 months, then monthly × 3 months
• Discontinued ketamine at month 14

2-Year Outcome: Remained in remission on duloxetine alone. Continued monthly therapy. Knows ketamine is available if needed.

Case 3: Tolerance Management

Patient: 52-year-old woman with chronic depression, initially excellent ketamine response.

Issue: After 6 months of every-2-week maintenance, noticed decreasing response duration. Symptoms returning by day 10.

Assessment: No new stressors, medications unchanged, confirmed adherence.

Management:

• Shortened to weekly × 4 weeks: response restored
• 6-week drug holiday
• Restarted at every 2 weeks: full response duration restored
• Added lithium augmentation to support response

Outcome: Maintained at every 2 weeks with lithium augmentation, stable for subsequent 18 months.

Strategic Takeaways

1. Plan for Maintenance from the Start: Discuss the likely need for ongoing treatment during informed consent. Set realistic expectations about treatment duration.

2. Individualize Frequency: There is no one-size-fits-all maintenance protocol. Use systematic interval extension to find each patient's optimal frequency.

3. Monitor Systematically: Implement regular safety monitoring including cognitive, urological, and hepatic assessments. Document comprehensively.

4. Prevent Tolerance Proactively: Appropriate spacing of treatments is the most effective tolerance prevention. Avoid unnecessary frequency escalation.

5. Optimize Concurrent Treatments: Use the window of ketamine response to maximize other evidence-based treatments. This creates opportunities for eventual transition.

6. Have a Long-Term Vision: Maintenance ketamine may be necessary for some patients indefinitely, while others can successfully transition. Individualized planning is essential.

7. Prepare for Transitions: When ready for discontinuation, use gradual tapers with clear relapse prevention plans. Maintain PRN access.

8. Stay Current: Long-term data continues to emerge. Update protocols as evidence evolves.

9. Address Practical Barriers: Cost, access, and lifestyle factors significantly impact maintenance success. Problem-solve proactively.

10. Celebrate Successes: Long-term maintenance often enables profound life improvements. Acknowledge the significance of sustained recovery for patients who have suffered for years.

References

Murrough JW, et al. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry, 74(4), 250-256.

Phillips JL, et al. (2019). Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. American Journal of Psychiatry, 176(5), 401-409.

Daly EJ, et al. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893-903.

Wajs E, et al. (2020). Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study. Journal of Clinical Psychiatry, 81(3), 19m12891.

aan het Rot M, et al. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry, 67(2), 139-145.